| 甲磺酸伊马替尼治疗手术无法切除的晚期胃肠间质瘤 |
| |
| 引用本文： | 岳欣, 胡均, 王家仓. 甲磺酸伊马替尼治疗手术无法切除的晚期胃肠间质瘤[J]. 中国肿瘤临床, 2016, 43(23): 1049-1052. DOI: 10.3969/j.issn.1000-8179.2016.23.043 |
| |
| 作者姓名： | 岳欣 胡均 王家仓 |
| |
| 作者单位： | 作者单位:天津医科大学肿瘤医院结直肠科,国家肿瘤临床医学研究中心,天津市肿瘤防治重实验室,天津市恶性肿瘤临床医学研究中心(天津市 300060) |
| |
| 摘 要： | 目的：探讨甲磺酸伊马替尼用于治疗晚期胃肠间质瘤的疗效及生存获益。方法：收集2004年9 月至2015年6 月天津医科大学肿瘤医院收治的无法手术切除的61例晚期胃肠间质瘤患者的临床资料，接受初始剂量400 mg/d 的口服甲磺酸伊马替尼治疗，定期随访，评价生存获益及药物不良反应。结果：61例患者开始接受治疗1 年后，治疗有效率为57.4%（35/ 61），疾病控制率为88.5%（54/ 61），Logic二元回归分析显示性别、年龄和腹盆腔多发病灶是影响治疗有效率的因素（P < 0.05）。 本组患者5 年累积生存率为53% ，Cox 回归模型分析提示腹盆腔的多发病灶是影响患者生存获益的重要因素（P < 0.05）。 除2 例患者出现出血，其余患者不良反应轻微。结论：甲磺酸伊马替尼显著改善晚期胃肠间质瘤的生存获益，可作为无法手术切除的晚期胃肠间质瘤的首选治疗。
|
| 关 键 词： | 胃肠间质瘤 甲磺酸伊马替尼 生存获益 靶向治疗 |
| 收稿时间： | 2016-09-12 |
| 修稿时间： | 2016-11-15 |
Imatinib mesylate for unresectable advanced gastrointestinal stromal tumors |
| |
| Xin YUE, Jun HU, Jiacang WANG. Imatinib mesylate for unresectable advanced gastrointestinal stromal tumors[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2016, 43(23): 1049-1052. DOI: 10.3969/j.issn.1000-8179.2016.23.043 |
| |
| Authors: | Xin YUE Jun HU Jiacang WANG |
| |
| Affiliation: | Department of Colorectal Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China |
| |
| Abstract: | Objective:To evaluate the response rate and survival benefit of imatinib mesylate for advanced gastrointestinal stromal tu-mors (GIST). Methods:Sixty-one patients with unresectable GIST were recruited and given imatinib mesylate with an initial oral dose of 400 mg/day and received regular follow-ups to evaluate the response rate, survival benefit, and adverse effects. Results:The re-sponse rate was 57.4%(35/61), and the disease control rate was 88.5%(54/61) one year after initial treatment. Analysis of the Logic regression model shows that gender, age, and multiple lesions in the abdominal and pelvic cavity are factors that affect response rate (P<0.05). The five-year cumulative survival rate is 53%. The status of multiple lesions in abdominal and pelvic cavity affected the surviv-al benefit of the cases (P<0.05). Although adverse effects frequently occur, most of them were mild except for two hemorrhagic cases. Conclusion:The clinical use of imatinib mesylate significantly increases the survival of patients with unresectable or metastatic GIST. The efficacy and safety of imatinib mesylate guarantees it as a treatment choice for advanced GIST. |
| |
| Keywords: | gastrointestinal stromal tumors imatinib mesylate survival benefit target therapy |
| 本文献已被 万方数据 等数据库收录！ |
| 点击此处可从《中国肿瘤临床》浏览原始摘要信息 |
|
点击此处可从《中国肿瘤临床》下载全文 |
|
